Imugene (ASX:IMU) share price jumps 6% on Japanese patent news

Imugene shares are climbing higher in afternoon trade today…

| More on:
female nurse in scrubs

Image source: Getty Images

The Imugene Ltd (ASX: IMU) share price is edging higher in afternoon trade on Wednesday and now trades at 48 cents apiece.

That’s a 5.5% gain on the day, well ahead of the S&P/ASX 200 Health Care index which has climbed 0.45%.

Imugene shares are on the move after the company announced a key patent update regarding one of its immunotherapies.

Here’s what we know.

Imugene share price jumps after patent approval

Imugene advised it was granted patent approval from the Japanese Patent Office for protection over its HER-Vaxx immunotherapy.

The HER-Vaxx regime is “currently in development” for a type of gastric malignancy known as HER2 positive gastric cancer.

As a result of the approval, the patent grants protection over “method of composition and method of use” for the biopharma company’s label.

This is the patent you’d want when applying for one – it covers the design and use of the product. That means Imugene’s rivals can’t copy how HER-Vaxx is made or copy its mechanism of action.

What’s more, the patent grants protection over the company’s technology until 2036, giving Imugene plenty of time to get things right.

The company’s announcement also notes that “approximately 75% of all gastric cancer diagnoses are in Asia”. It’s an alarming statistic compounded by the fact Japan has “the thirst highest incidence of gastric cancer worldwide”.

Of these cases, “approximately one in five” is diagnosed as HER2 positive which means the market for HER-Vaxx is large. The potential to make a meaningful difference is equally as large.

What did management say?

Speaking on the announcement, Imugene’s CEO Leslie Chong said:

Attaining the key Japanese patent is an important milestone. This adds extra value to Imugene’s portfolio of B-cell immunotherapies and this will protect them in one of the world’s largest HER2 positive gastric cancer markets until 2036.

Imugene share price snapshot

The Imugene share price has been a major outperformer this year to date, posting a return of 380% since January 1.

In the last month alone, Imugene shares have climbed a further 68% into the green.

This extends the return over the previous 12 months to 943%, well ahead of the broad index’s gain of around 25% over the past year.

Should you invest $1,000 in Imugene right now?

Before you consider Imugene, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Imugene wasn't one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers